ADMA BIOLOGICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-09-01: Study NCT05070455; Company role Lead sponsor; Phase Phase 4; Status Unknown.
- 2016-12-29: Study NCT03164967; Company role Lead sponsor; Phase Phase 4; Status Completed.
- 2016-12: Study NCT03037359; Company role Lead sponsor; Phase Observational; Status Unknown.
- 2014-02: Study NCT01814800; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-09-01 | NCT05070455 An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) | Lead sponsor | Phase 4 | Unknown | Primary Immune Deficiency | 12 | 2023-06-30 |
| 2016-12-29 | NCT03164967 Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16 | Lead sponsor | Phase 4 | Completed | Humoral Immune Response | 16 | 2022-12-31 |
| 2016-12 | NCT03037359 A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products | Lead sponsor | Observational | Unknown | Primary Immune Deficiency Disorder | 200 | 2023-06-30 |
| 2014-02 | NCT01814800 Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) | Lead sponsor | Phase 3 | Completed Results posted | Primary Immune Deficiency Disorder | 59 | 2015-01 |
| 2008-02 | NCT00632463 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness | Lead sponsor | Phase 2 | Completed Results posted | Upper Respiratory Tract Infection; Lower Respiratory Tract Infection | 21 | 2010-05 |
| 2007-09 | NCT00538915 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) | Lead sponsor | Phase 3 | Completed Results posted | Primary Immune Deficiency Disorders (PIDD) | 63 | 2009-07 |
| 2007-05 | NCT00473824 Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation | Lead sponsor | Phase 2 | Terminated Results posted | Sequelae of Viral Hepatitis; Transplantation Infection; Evidence of Liver Transplantation | 7 | 2009-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |